[
  {
    "ts": null,
    "headline": "Intellia Focuses on Pipeline Development Amid Stiff Competition",
    "summary": "Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.",
    "url": "https://finnhub.io/api/news?id=8195ef88c62076e0d29f7e1998b1800e0b7f49a7f07c30bf70afca5baf173fc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743430200,
      "headline": "Intellia Focuses on Pipeline Development Amid Stiff Competition",
      "id": 133627901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.",
      "url": "https://finnhub.io/api/news?id=8195ef88c62076e0d29f7e1998b1800e0b7f49a7f07c30bf70afca5baf173fc1"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space",
    "summary": "ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.",
    "url": "https://finnhub.io/api/news?id=c9571d0a3c4c4d14e33bb28efac4574b91358be920e5e0a8da5ba1fbe0a06304",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743426600,
      "headline": "3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space",
      "id": 133627961,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.",
      "url": "https://finnhub.io/api/news?id=c9571d0a3c4c4d14e33bb28efac4574b91358be920e5e0a8da5ba1fbe0a06304"
    }
  }
]